RECURSION PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 0.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2025-02-28
- RECURSION PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was 0.00%.
- RECURSION PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -0.10%, a 112.50% decline from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was 0.80%, a 33.33% increase from fiscal 2021.
- RECURSION PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2021 was 0.60%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2024-12-31 | 0.00% 10-K · filed 2025-02-28 |
| 2023-12-31 | -0.10% 10-K · filed 2025-02-28 |
| 2022-12-31 | 0.80% 10-K · filed 2025-02-28 |
| 2021-12-31 | 0.60% 10-K · filed 2024-02-29 |
| 2020-12-31 | -0.50% 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |